Moreover, PRT543 induces significant antitumor effects in ACC patient-derived xenograft (PDX) models expressing PRMT5 and MYC. Furthermore, we show that lenvatinib (the FDA approved multi-kinase inhibitor used to treat patients with advanced stage recurrent and metastatic ACC [46, 47]) enhances growth inhibitory effect of PRT811 in vitro, suggesting a potential clinical benefit for patients expressing lenvatinib favorable molecular profile. The gene discussed is MYC; the disease is adrenal cortex carcinoma.